(Q36219690)

English

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab (English)

1 reference

Europe PubMed Central

12 August 2017

follicular lymphoma

1 reference

based on heuristic

inferred from title

14

object named as

Sergio Giralt

1 reference

Europe PubMed Central

12 August 2017

8

object named as

Luis Fayad

0 references

Sattva S Neelapu

15

object named as

Sattva S Neelapu

1 reference

Europe PubMed Central

12 August 2017

19

object named as

Larry W Kwak

1 reference

Europe PubMed Central

12 August 2017

Fredrick B Hagemeister

18

object named as

Fredrick Hagemeister

1 reference

Europe PubMed Central

12 August 2017

Peter J McLaughlin

2

object named as

Peter McLaughlin

1 reference

Europe PubMed Central

12 August 2017

Felipe Samaniego

9

object named as

Felipe Samaniego

1 reference

Europe PubMed Central

12 August 2017

L Jeffrey Medeiros

7

object named as

L Jeffrey Medeiros

1 reference

Europe PubMed Central

12 August 2017

4

object named as

Chitra Hosing

1 reference

Europe PubMed Central

12 August 2017

10

object named as

Amin Alousi

1 reference

Europe PubMed Central

12 August 2017

Richard E Champlin

20

object named as

Richard E Champlin

1 reference

Europe PubMed Central

12 August 2017

3

object named as

Rima M Saliba

1 reference

Europe PubMed Central

12 August 2017

Martin Körbling

5

object named as

Martin Korbling

1 reference

Europe PubMed Central

12 August 2017

1

object named as

Issa F Khouri

1 reference

Europe PubMed Central

12 August 2017

Baruch Samuel Blumberg

17

object named as

Barry I Samuels

1 reference

Europe PubMed Central

12 August 2017

author name string

Ming S Lee

6

1 reference

Europe PubMed Central

12 August 2017

Paolo Anderlini

11

1 reference

Europe PubMed Central

12 August 2017

Daniel Couriel

12

1 reference

Europe PubMed Central

12 August 2017

Marcos de Lima

13

1 reference

Europe PubMed Central

12 August 2017

Naoto T Ueno

16

1 reference

Europe PubMed Central

12 August 2017

language of work or name

0 references

publication date

14 April 2008

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

111

1 reference

Europe PubMed Central

12 August 2017

5530-5536

1 reference

Europe PubMed Central

12 August 2017

12

1 reference

Europe PubMed Central

12 August 2017

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

1 October 2017

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

1 October 2017

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

1 October 2017

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

1 October 2017

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

1 October 2017

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

1 October 2017

1994 Consensus Conference on Acute GVHD Grading

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

1 October 2017

Quantification of bcl-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

29 June 2018

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

22 September 2018

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

22 September 2018

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

22 September 2018

Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

22 September 2018

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

22 September 2018

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

22 September 2018

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

22 September 2018

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

22 September 2018

CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

21 October 2018

Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

5 December 2018

Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4624452

5 December 2018

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic bone marrow transplantation for low-grade lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative assessment of disease involvement by follicular lymphoma using real-time polymerase chain reaction measurement of t(14;18)-carrying cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical trial of anti-idiotype therapy for B cell malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18411419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2008-01-136242

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36219690&oldid=1835215495"